drugset
drugset / Trial / NCT01017185

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

NCT01017185 ↗

Phase 1 Completed 28 enrolled Takara Bio Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether HF10 is safe and effective in the treatment of head and neck cancer or solid tumors with cutaneous and/or superficial lesions.

Timeline

Start
2009-08
Primary completion
2014-05
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CANERPATUREV Other / unclassified 100000 unknown Other
Subject CANERPATUREV Other / unclassified 300000 unknown Other
Subject CANERPATUREV Other / unclassified 1e+06 unknown Other
Subject CANERPATUREV Other / unclassified 1e+07 unknown Other

Indications

breast carcinoma head and neck cancer melanoma skin squamous cell carcinoma